banner leadership

Robert Davidson

Chief Executive Officer

Jessica Rousset

Chief Operating Officer

Michael Redard

Chief Financial Officer

Mark Udell

Chief Accounting Officer

Steven Ruhl

VP of Manufacturing

Vered Gigi, PhD

VP of Strategy and Business Development

Gary Speier, MS, JD, MBA

Intellectual Property Counsel

Paul T. Sudhakar, MS, MBA

Regulatory Counsel

CLOSE X

Robert Davidson

Robert Davidson is CURE’s CEO. Prior to his role at CURE Pharmaceutical, Robert Davidson served as President and Chief Executive Officer of InnoZen Inc., Chief Executive Officer of Gel Tech LLC, Chief Executive Officer of Bio Delivery Technologies Inc., and has served on multiple corporate boards. Mr. Davidson was responsible for the development of several drug delivery technologies and commercial brand extensions. He has worked with brands such as Chloraseptic™, Suppress™, as well as Pediastrip™, a private label electrolyte oral thin film sold in major drug store chains. Mr. Davidson received his B.S. degree with a concentration in Biological Life Sciences. He has a Masters Certificate in Applied Project Management from Villanova University, Masters of Public Health from American Military University, Virginia and a Masters in Health and Wellness from Liberty University, Virginia. Davidson also completed his Post Graduate Studies at the University of Cambridge with letter of commendation.

CLOSE X

Jessica Rousset

Jessica Rousset is CURE’s Chief Operating Officer. Mrs. Rousset oversees operations and drives corporate strategy and growth. She is a seasoned business development and commercialization leader, expert in bridging corporate, academic and governmental interests toward the common goal of improving patient’s lives. She brings more than fifteen years of experience fostering innovation in large organizations and advising start-ups to bring novel healthcare solutions to market and into clinical use. Mrs. Rousset previously served as Head of Innovation at Children’s Hospital Los Angeles, where over a ten year period, she helped launch both therapeutic and medical device companies and founded and operated a national pediatric technology accelerator. Prior to that, Mrs. Rousset held positions at The Scripps Research Institute and GlaxoSmithkline Biologicals in laboratory, clinical research and business development roles. She trained as a biochemical engineer at the Institut National des Sciences Appliquées in Lyon, France.

CLOSE X

Michael Redard

Mr. Redard is a seasoned executive with over 30 years of experience in financial operations, strategic planning and capital markets. His career has spanned a broad range of industries including medical devices, healthcare, consumer products, and manufacturing.

Prior to CURE, Redard held CFO, vice president and general manager positions with several venture and private equity backed companies including Inogen, Medical Analysis Systems (acquired by Thermo Fisher Scientific), CDTi Advanced Materials, and Abrisa Technologies. Earlier experience includes management roles with Pepsi and in public accounting.

He is a CPA (inactive) and received his B.S. in Business Administration from California Polytechnic State University, San Luis Obispo.

CLOSE X

Mark Udell

Mark Udell is CURE’s Chief Accounting Officer, Treasurer and Secretary. Mr. Udell is responsible for all strategic tactical matters as they relate to budget management, cost benefit analysis, forecasting need, securing of new funding and overseeing the management and coordination of all fiscal reporting activities for the organization. He is a Certified Public Accountant with over 17 years of experience in finance and accounting. Prior to joining CURE Pharmaceutical in 2011, Mr. Udell served as InnoZen, Inc.’s Chief Accounting Officer and Controller and was responsible for establishing, monitoring and enforcing policies and procedures for the company as well as conducting audits and working with external auditors. While working at CURE and InnoZen, Inc., Mr. Udell gained valuable knowledge in the drug delivery industry and is a key contributor in the development and commercialization of various drug delivery technologies. He has also held the position as Auditing Manager at Green Hasson & Janks, LLP in Los Angeles. Mr. Udell received his B.A. in Business Economics with a concentration in accounting from the University of California, Santa Barbara.

CLOSE X

Steven Ruhl

Steven Ruhl is CURE’s VP of Manufacturing, overseeing all process development and manufacturing operations. He is a seasoned leader for drug substance and drug products process development, production facility design, process equipment, construction and CGMP management.  He has a proven track record with building and developing high performing teams to deliver commercial supply and process solutions that meet regulatory requirements. Mr. Ruhl brings more than 35 years of experience leading technical teams.  Most recently he served 11 years at Amgen Thousand Oaks in multiple process development roles. As Process Development Director of Generation Technologies he led the introduction and commissioning of a next generation isolated drug product robotic filler.  Prior to that he served 4 years at Amgen Technologies Ireland as Process Development Site and Tech Transfer Program Lead for multiple Amgen Commercial products where he co-led a $350M capital expansion of an Amgen acquired Pfizer site to expand site capabilities to manufacture, package and cold store finished drug product.  Steven entered Amgen in 2007 as Commercial Drug Product Executive Director responsible for global support and lifecycle management of Amgen’s commercial products. Previously, Steven held management positions at CancerVax, Certified Facilities, IDEC Pharmaceuticals, Xoma and Celtrix Pharmaceuticals.  He served IDEC during the time of two firsts for monoclonal antibody therapies with development and launch of Rituxan® and co-led the CMC development for Zevalin® radioimmune conjugate. He trained as microbiologist and chemist at Brigham Young University.

CLOSE X

Vered Gigi, PhD

Dr. Vered Gigi is CURE’s VP of Strategy and Business Development (BD). As VP of strategy and BD, Dr. Gigi is responsible for the corporate development by identifying and shaping CURE’s strategy both organically and inorganically to deliver sustained growth and diversified revenue. She is also responsible for building and maintaining relationships with the pharmaceutical companies, academia and other collaborators. Together with the office of the COO, her charter is to drive operational excellence and competitiveness. Prior to joining CURE, Dr. Gigi was a Project Leader with the Boston Consulting Group. During her tenure, she led and supported a variety of projects at global biopharma and medtech companies with a focus on corporate and network strategy, operations, marketing and post-merger integration initiatives. Dr. Gigi holds a PhD in Immunology from the University of Pennsylvania and a BSc. in Bio-Medical sciences from Tel-Aviv University in Israel. During her years in academia she investigated immunotherapy, stem cell and DNA repair mechanisms.

CLOSE X

Gary Speier, MS, JD, MBA

Gary is a registered U.S. patent attorney and a partner at Carlson Caspers with over 25 years experience in pharmaceutical patent law. He provides counsel on a broad range of patent-related matters and regularly conducts pre-suit investigations, intellectual property valuations and IP due diligence. Gary provides freedom-to-operate clearance reviews and opinions relating to infringement and validity, and develops patent procurement and patent prosecution strategies for domestic, international, and foreign jurisdictions. He has been involved in numerous post-grant proceedings (e.g., ex parte reexaminations and inter partes reviews) in front of the U.S. Patent and Trademark Office (USPTO). Gary has a strong technical and scientific background, as well as extensive, firsthand experience in USPTO practice and procedure. For the past several years, Gary has devoted significant time to preparing opinions relating to pharmaceutical patents, and has prepared and served numerous Hatch Waxman “Paragraph IV” notice letters and detailed statements. He also has represented generic pharmaceutical companies in ANDA patent litigations. Gary holds a JD from Temple University School of Law, an MBA from the University of Massachusetts, Amherst, M.Sc. Chemistry from Villanova University, B.Sc. Chemistry from Fordham University. He is admitted to the Supreme Courts of MN, NJ, ND and PA, the U.S. District Court for the District of NJ, U.S. Court of Appeals for the Federal Circuit and the U.S. Patent and Trademark Office.

CLOSE X

Paul T. Sudhakar, MS, MBA

Paul Sudhakar is the President and CEO of PTS Consulting, LLC and has over 30 years of experience in the pharmaceutical and related industries. Paul has been actively involved in product development activities including broad range regulatory support activities consisting of but not limited to, preclinical, clinical, bioequivalence studies, chemistry & manufacturing controls and filing/approval of drug applications. He is involved in FDA review management of drug and biologic and device applications and regulatory/approval/launch activities for numerous products some of which require circumventing of patents and exclusivities. Paul held leadership positions at Midland Pharmaceutical, ratiopharm GmbH (now Teva), Martec Scientific (now Nostrum Lab) and Martec Pharmaceutical. Managed inception to commercialization (marketing and sales) of various products and filed numerous ANDA products and obtained approvals for several these products with significant brand sales in the US and European market. Paul hold a B.S. and M.S. in Pharmacy from the University Department of Chemical Technology, India, an M.B.A. from Andrews University, Michigan and Kansas State University, Kansas.